Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: This product is assembled upon order. Please allow up to three weeks for your product to be processed

Pricing & Additional Information

To learn more about our Blocking Peptides, including pricing, please answer a few questions.

Pricing & Additional Information  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using Cyclin D1 (92G2) Rabbit mAb #2978 in the presence of control peptide (left) or Cyclin D1 Blocking Peptide (right).

Learn more about how we get our images
Image

Product Description

This peptide is used to block Cyclin D1 (92G2) Rabbit mAb #2978 reactivity.


Quality Control

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks Cyclin D1 (92G2) Rabbit mAb #2978 by immunohistochemistry.

Product Usage Information

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 μl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.


Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.

Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins (1). The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase (2). The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression (3). Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation (4).


1.  Sherr, C.J. (1996) Science 274, 1672-7.

2.  Lukas, J. et al. (1996) Mol Cell Biol 16, 6917-25.

3.  Hirai, H. et al. (1995) Mol Cell Biol 15, 2672-81.

4.  Diehl, J.A. et al. (1997) Genes Dev. 11, 957-972.


Entrez-Gene Id 595
Swiss-Prot Acc. P24385


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.